Advertisement

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review

  • Ivan UritsEmail author
  • Mark R. Jones
  • Kyle Gress
  • Karina Charipova
  • Jacob Fiocchi
  • Alan D. Kaye
  • Omar Viswanath
Other Pain (A Kaye and N Vadivelu, Section Editors)
  • 54 Downloads
Part of the following topical collections:
  1. Topical Collection on Other Pain

Abstract

Purpose of Review

The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist.

Recent Findings

Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers.

Summary

CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.

Keywords

Chronic migraines Episodic migraines Calcitonin gene receptor peptide (CGRP) antagonist Erenumab 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ivan Urits, Mark R. Jones, Kyle Gress, Karina Charipova, Jacob Fiocchi, and Omar Viswanath declare no conflict of interest. Dr. Kaye is a speaker for Depomed, Inc. and Merck, Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bajwa ZH, Wootton RJ, Wippold FJ II. Evaluation of headache in adults. UpToDate. 2018.Google Scholar
  2. 2.
    Society IH. The International Classification of Headache Disorders, 3rd edn. 2018.Google Scholar
  3. 3.
    Cutrer FM, Bajwa ZH. Pathophysiology, clinical manifestations, and diagnosis of migraine in adults. UpToDate. 2017.Google Scholar
  4. 4.
    Russo A. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533–52.CrossRefGoogle Scholar
  5. 5.
    Giffin N, Lipton R, Silberstein J, Olesen S, Goadsby P. The migraine postdrome: an electronic diary study. Neurology. 2016;87:309–13.CrossRefGoogle Scholar
  6. 6.
    Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98:4687–92.CrossRefGoogle Scholar
  7. 7.
    Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004;113:1447–55.CrossRefGoogle Scholar
  8. 8.
    Karatas H, Erdener S, Gursoy-Ozdemir Y, Lule S, Eren-Koçak E, Sen Z, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science. 2013;339:1092–5.CrossRefGoogle Scholar
  9. 9.
    Lipton R, Stewart W, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.CrossRefGoogle Scholar
  10. 10.
    Lipton R, Bigal M, Diamond M, Freitag F, Reed M, Stewart W, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.CrossRefGoogle Scholar
  11. 11.
    Stewart W, Wood C, Reed M, Roy J, Lipton R, Group AA. Cumulative lifetime migraine incidence in women and men. Cephalagia. 2008;28:1170–8.CrossRefGoogle Scholar
  12. 12.
    Martin V, Behbehani M. Toward a rational understanding of migraine trigger factors. Med Clin North Am. 2001;85:911–41.CrossRefGoogle Scholar
  13. 13.
    Kelman L. The triggers or precipitants of the acute migraine attack. Cephalagia. 2007;27:394–402.CrossRefGoogle Scholar
  14. 14.
    Bajwa ZH, Smith JH. Preventive treatment of migraine in adults. UpToDate. 2018.Google Scholar
  15. 15.
    Goadsby P, Lipton R, Ferrari M. Migraine—current understanding and treatment. N Engl J Med. 2002;346:257–70.CrossRefGoogle Scholar
  16. 16.
    Bajwa ZH, Smith JH. A cute treatment of migraine in adults. UpToDate. 2018.Google Scholar
  17. 17.
    Breeze A, Harvey T, Bazzo R, Campbell I. Solution structure of human calcitonin gene-related peptide by 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry. 1991;30:575–82.CrossRefGoogle Scholar
  18. 18.
    Sexton P, Christopoulos G, Christopoulos A, Nylen E, Snider R Jr, Becker K. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med. 2008;36:1637–40.CrossRefGoogle Scholar
  19. 19.
    Muddhrry PK, Ghatki MA, Spokks RA, Jonhs PM, Pierson AM, Hamid Q, et al. Differential expression of α-CGRP and β-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25:195–205.CrossRefGoogle Scholar
  20. 20.
    Poyner D, Sexton P, Marshall I, Smith D, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharm Rev. 2002;54:233–46.CrossRefGoogle Scholar
  21. 21.
    Zhang Z, Winborn C, Marquez de Prado B, Russo A. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27:2693–703.CrossRefGoogle Scholar
  22. 22.
    Archbold J, Flanagan J, Watkins H, Gingell J, Hay D. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol Sci. 2011;32:591–600.CrossRefGoogle Scholar
  23. 23.
    Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57:47–55.CrossRefGoogle Scholar
  24. 24.
    Walker CS, Conner AC, Poyner DR, Hay DL. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci. 2010;31:476–83.CrossRefGoogle Scholar
  25. 25.
    Walker C, Sajedeh E, Bower RL, Wilderman A, Insel PA, Edvinsson L, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2:595–608.CrossRefGoogle Scholar
  26. 26.
    Walker C, Hay D. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin andamylin receptors? Br J Pharmocol. 2013;170:1293–307.CrossRefGoogle Scholar
  27. 27.
    McCulloch J, Uddman R, Kingman T, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A. 1986;83:5731–5.CrossRefGoogle Scholar
  28. 28.
    Goadsby P, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–7.CrossRefGoogle Scholar
  29. 29.
    Goadsby P, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56.CrossRefGoogle Scholar
  30. 30.
    Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalagia. 2002;22:54–61.CrossRefGoogle Scholar
  31. 31.
    Lennerz J, Rühle V, Ceppa E, Neuhuber W, Bunnett N, Grady E, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507:1277–99.CrossRefGoogle Scholar
  32. 32.
    Russo A, Kuburas A, Kaiser E, Raddant A, Recober A. A potential preclinical migraine model: CGRP-sensitized mice. Mol Cell Pharmocol. 2009;1:264–70.Google Scholar
  33. 33.
    Coull J, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438:1017–21.CrossRefGoogle Scholar
  34. 34.
    Souslova V, Cesare P, Ding Y, Akopian A, Stanfa L, Suzuki R, et al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature. 2000;407:1015–7.CrossRefGoogle Scholar
  35. 35.
    MacKenzie ET, Edvinsson LSB. Functional bases for a central serotonergic involvement in classic migraine: a speculative view. Cephalalgia. 1985;5:69–781.CrossRefGoogle Scholar
  36. 36.
    Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49:1258–66.CrossRefGoogle Scholar
  37. 37.
    •• Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–32 Important STRIVE phase 3 trial demonstrating efficacy of erenumab for the prevention of episodic migraines. CrossRefGoogle Scholar
  38. 38.
    Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80:193–9.CrossRefGoogle Scholar
  39. 39.
    Hostetler ED, Joshi AD, Sanabria-Bohorquez S, Fan H, Zeng Z, Purcell M, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013;347:478–86.CrossRefGoogle Scholar
  40. 40.
    Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6:534–47.CrossRefGoogle Scholar
  41. 41.
    Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. Informa UK Ltd. 2018;21:666–75.CrossRefGoogle Scholar
  42. 42.
    Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm Res Pharm Res. 2017;34:1784–95.PubMedGoogle Scholar
  43. 43.
    de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;103:815–25.CrossRefGoogle Scholar
  44. 44.
    Giamberardino MA, Affaitati G, Costantini R, Cipollone F, Martelletti P. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res. 2017;10:2751–60.CrossRefGoogle Scholar
  45. 45.
    •• Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: the phase 2 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37 The ARISE Phase 3 trial of erenumab for the prevention of episodic migraines. CrossRefGoogle Scholar
  46. 46.
    Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58:715–23.CrossRefGoogle Scholar
  47. 47.
    de Hoon J, Van Hecken A, Vandermeulen C, Herbots M, Kubo Y, Lee E, et al. Phase I, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia. 2018;0:1–11.Google Scholar
  48. 48.
    Markham A. Pegvaliase: first global approval. Drugs. 2018;78:1157–61.CrossRefGoogle Scholar
  49. 49.
    Reinke T. Aimovig for migraine prevention: the new kid may have trouble fitting in. Manag Care. 2018;27:10–1.PubMedGoogle Scholar
  50. 50.
    Traynor K. FDA approves licensing of erenumab-aooe to prevent migraine. Am J Heal Pharm. 2018;75:929–30.Google Scholar
  51. 51.
    Choy M. Pharmaceutical approval update. Pharm Ther. 2018;43:461–2.Google Scholar
  52. 52.
    •• Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–34 Excellent phase 2 randomized controlled trial demonstrating the safety and efficacy of erenumab for the treatment of chronic migraines. CrossRefGoogle Scholar
  53. 53.
    Traynor J. μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2011;121:173–80.CrossRefGoogle Scholar
  54. 54.
    • Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. Elsevier Ltd; 2014;13:1100–1107. Excellent phase 2 trial of Eptinezumab for the prevention of frequent episodic migraine. Google Scholar
  55. 55.
    • Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials. Cephalalgia. 2018;0:1–9 A phase 2 trial of Fremanezumab for the treatment of episodic and chronic migraines. Google Scholar
  56. 56.
    • Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine. JAMA Neurol. 2018;85054. Excellent review of Galcanezumab for the treatment of episodic migraines. Google Scholar
  57. 57.
    Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics. 2018;15:324–35.CrossRefGoogle Scholar
  58. 58.
    Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10:183–203.CrossRefGoogle Scholar
  59. 59.
    Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014;6:871–8.CrossRefGoogle Scholar
  60. 60.
    Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34:968–76.CrossRefGoogle Scholar
  61. 61.
    Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2014;34:483–92.CrossRefGoogle Scholar
  62. 62.
    Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22.CrossRefGoogle Scholar
  63. 63.
    Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:1–11.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ivan Urits
    • 1
    Email author
  • Mark R. Jones
    • 1
  • Kyle Gress
    • 2
  • Karina Charipova
    • 2
  • Jacob Fiocchi
    • 3
  • Alan D. Kaye
    • 4
  • Omar Viswanath
    • 5
    • 6
    • 7
  1. 1.Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain MedicineHarvard Medical SchoolBostonUSA
  2. 2.Georgetown University School of MedicineWashingtonUSA
  3. 3.Creighton University School of Medicine-Phoenix Regional CampusPhoenixUSA
  4. 4.Department of AnesthesiologyLouisiana State University Health Sciences CenterNew OrleansUSA
  5. 5.Valley Anesthesiology and Pain ConsultantsPhoenixUSA
  6. 6.University of Arizona College of Medicine-PhoenixPhoenixUSA
  7. 7.Creighton University School of MedicineOmahaUSA

Personalised recommendations